A population-based analysis of statin utilization in British Columbia

Clinical Therapeutics

Volumn 29, Issue 9, 2007, Pages 2107-2119

  Raymond, Colette B ^a   Morgan, Steven G ^b   Katz, Alan ^c   Kozyrskyj, Anita L ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

cholesterol treatment; claims data; drug utilization; pharmacoepidemiology

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CANADA; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DRUG UTILIZATION; DYSLIPIDEMIA; FEMALE; HEALTH INSURANCE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; POPULATION RESEARCH; TREND STUDY;

ADULT; AGED; AGED, 80 AND OVER; BRITISH COLUMBIA; CARDIOVASCULAR DISEASES; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG;

EID: 36849021158     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.09.022     Document Type: Article

References (65)

1. IMS. Available at:. Leading therapy classes by global pharmaceutical sales (2005). http://www.imshealth.com/ims/portal/front/articleC/027776599774785797747 968300.html Accessed August 2006
2. Morgan S. Drug spending in Canada: Recent trends and causes. Med Care. 42 (2004) 635-642
3. McPherson R., Frohlich J., Fodor G., and Genest J. for the Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement-recommendations for the diagnosis and treatment ofdyslipidemia and prevention of cardiovascular disease [published correction appears in CanJ Cardiol. 2006;22:1077]. CanJ Cardiol. 22 (2006) 913-927
4. Shepherd J., Blauw G., Murphy M., et al. for the PROSPER Study Group (PROspective Study of Pravastatin in the Elderly at Risk). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360 (2002) 1623-1630
5. Cheung B., Lauder I., Lau C., and Kumana C. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Olin Pharmacol. 57 (2004) 640-651
6. Manuel D., Tanuseputro P., Mustard C., et al. The 2003 Canadian recommendations for dyslipidemia management: Revisions are needed [published correction appears in CMAJ. 2005;173:133]. CMAJ 172 (2005) 1027-1031
7. Genest J., McPherson R., Frohlich J., and Fodor G. The analysis by Manuel and colleagues creates controversy with headlines, not data. CMAJ 172 (2005) 1033-1034 discussion 1037
8. Bennett K., Williams D., and Feely J. Under-prescribing of cardiovascular therapies for diabetes in primary care. EurJ Clin Pharmacol. 58 (2003) 835-841
9. Bjerrum L., Larsen J., and Kragstrup J. Guidelines accompanied by changes in reimbursement rules. Effects on lipid-lowering drug prescribing. ScandJ Prim Health Care 19 (2001) 158-162
10. Degli Esposti L., Di Martino M., Saragoni S., et al. Pharmacoutilization ofstatin therapy after acute myocardial infarction. A real practice analysis based on administrative data. Ital HeartJ 5 (2004) 120-126
11. DeWilde S., Carey I., Bremner S., et al. Evolution of statin prescribing 1994-2001: A case ofagism but not of sexism?. Heart 89 (2003) 417-421
12. Dubois R., Alexander C., Wade S., et al. Growth in use of lipid-lowering therapies: Are we targeting the right patients?. AmJ Manag Care 8 (2002) 862-867
13. Feely J., McGettigan P., and Kelly A. Growth in use ofstatins after trials is not targeted to most appropriate patients. Clin Pharmacol Ther. 67 (2000) 438-441
14. Foody J., Ferdinand F., Galusha D., et al. Patterns of secondary prevention in older patients undergoing coronary artery bypass grafting during hospitalization for acute myocardial infarction. Circulation 108 Suppl I (2003) 1124-1128
15. Hartz I., Eggen A., and Grimsgaard S. et al. Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: The Tromso Study 2001. EurJ Clin Pharmacol 60 (2004) 643-649
16. Kanstrup H., Lassen J., Heickendorff L., et al. Quality of lipid-lowering therapy in patients with ischaemic heart disease: A register-based study in 3477 patients. J Intern Med 255 (2004) 367-372
17. Kopjar B., Sales A., Pineros S., et al. Comparison of characteristics of patients with coronary heart disease receiving lipid-lowering therapy versus those not receiving such therapy. AmJ Cardiol 91 (2003) 1352-1354
18. Kucera Z., Vlcek J., and Hejdova M. Theoretical exposure of chronically treated patients to lipid lowering agents. Pharmacoepidemiol Drug Saf 14 (2005) 61-67
19. Lewis B. McDonough K. Dyslipidemia treatment among patients with coronary artery disease in a managed care organization. Am J Health Syst Pharm 61 (2004) 1032-1038
20. Majeed A., Moser K., and Maxwell R. Age, sex and practice variations in the use of statins in general practice in England and Wales. J Public Health Med 22 (2000) 275-279
21. for the Canadian Cardiovascular Outcomes Research Team. Pilote L., Beck C., Karp I., et al. Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997-2000. Can J Cardiol 20 (2004) 61-67
22. Rasmussen I., Gislason G., Abildstrom S., et al. Statin use after acute myocardial infarction: A nationwide study in Denmark [published correction appears in BrJ C/in Pharmacol. 2005;60:343]. Br J C/in Pharmacot. 60 (2005) 150-158
23. Siegel D., and Lopez J. Meier J. Use of cholesterol-lowering medications in the United States from 1991 to 1997. AmJ Med 108 (2000) 496-499
24. Teeling M., and Bennett K. FeelyJ. The influence of guidelines on the use of statins: Analysis of prescribing trends 1998-2002. Br J Clin Pharmacol 59 (2005) 227-232
25. Williams D., and Bennett K. Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol 55 (2003) 604-608
26. Yang C., and Jick S. Testa MA. Who receives lipid-lowering drugs: The elfects of comorbidities and patient characteristics on treatment initiation. Br J Clin Pharmacol 55 (2003) 288-298
27. Cooke C., Nissen L., Sketris I., and Tett S. Quantifying the use of the statin antilipemic drugs: Comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia. C/in Ther. 27 (2005) 497-508
28. for the Canadian Cardiovascular Outcomes Research Team. Jackevicius C., Tu K., Filate W., et al. Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. Can J CardioL 19 (2003) 1359-1366
29. Larsen J., Andersen M., and Kragstrup J. Gram LF. Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993-1998)in a Danish population. Eur J Clin Pharmacol 57 (2001) 343-348
30. Levy A., O'Brien B., McMullen E., et al. Rapid increase in statins newly dispensed to Ontario seniors between 1994 and 2000. CanJ Cardiol 19 (2003) 665-669
31. Magrini N., Einarson T., Vaccheri A., et al. Use of lipid-lowering drugs from 1990 to 1994: An international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. EurJ Clin Pharmacol 53 (1997) 185-189
32. Martikainen J., Klaukka T., and Reunanen A. et al. Recent trends in the consumption of lipid-lowering drugs in Finland. J Clin Epidemiol 49 (1996) 1453-1457
33. Packham C., Pearson J., Robinson J., and Gray D. Use of statins in general practices, 1996-8: Cross sectional study. BMJ 320 (2000) 1583-1584
34. Savoie I. Kazanjian A. Utilization of lipid-lowering drugs in men and women. A reflection of the research evidence? J Clin Epidemiol 55 (2002) 95-101
35. Ko D., and Mamdani M. Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: The treatment-risk paradox.JAMA 291 (2004) 1864-1870
36. for the EuroMedStat Group. Walley T., Folino-Gallo P., Schwabe U., and van Ganse E. Variations and increase in use of statins across Europe: Data from administrative databases [published correction appears in BMJ. 2004;329:323]. BMJ 328 (2004) 385-386
37. Metge C., Kozyrskyj A., Dahl M., et al. Drug prescribing in Manitoba: How appropriate is it? (2003), Manitoba Centre for Health Policy, Winnipeg, Manitoba, Canada
38. Silwer L., and Lundborg C. Patterns of drug use during a 15 year period: Data from a Swedish county, 19882002. Pharmacoepidemiol Drug Saf 14 (2005) 813-820
39. Walley T., Folino-Gallo P., and Stephens P. Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J C/in Pharmacol 60 (2005) 543-551
40. Paterson J., Carney G., Anderson G., et al. for the BC-Ontario Pharmacosurveillance for Decision making Collaborative. Case selection for statins was similar in two Canadian provinces: BC and Ontario. J Clin Epidemiol 60 (2007) 73-78
41. Riahi S., Fonager K., Tort E., et al. Use of lipid-lowering drugs during 1991-98 in Northern Jutland, Den- mark. BrJ Clin Pharmacol 52 (2001) 307-311
42. World Health International Classification of Diseases, 9th Revision, 2003
43. Available at:. http://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICDg/1998 Accessed August 2, 2007
44. Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures. Ottawa, ON: Statistics Canada; 1986. Catalog no. 82-562-XPE.
45. ACG Software Documentation and Users Manual (2001), Johns Hopkins University, Baltimore, Md
46. Norwegian Institute of Public Health. Guidelines for ATC Classification and DDD Assignment. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2003.?
47. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada. Tri-Council Policy Statement." Ethical Conduct for Research Involving Humans. 1998 (with 2000, 2002 and 2005 amendments)
48. Available at:. http://pre.ethics.gc.ca/english/policystatement/policystatement.cfm Accessed August 13,2007
49. Foody J., Rathore S., and Galusha D. et al. HydroxymethylglutaryI-CoA reductase inhibitors in older persons with acute myocardial infarction: Evidence for an age-statin interaction. J Am Geriatr Soc 54 (2006) 421-430
50. Andrawes W., and Bussy C. Belmin J. Prevention of cardiovascular events in elderly people. Drugs Aging 22 (2005) 859-876
51. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo controlled trial. Lancet 360 (2002) 7-22
52. Walsh J. Pignone M. Drug treatment of" hyperlipidemia in women. JAMA 291 (2004) 2243-2252
53. for the SESAMI Study Group. Alter D., Iron K., Austin P., and Naylor C. Influence of education and income on atherogenic risk factor profiles among patients hospitalized with acute myocardial infarction. Can J Cardiol 20 (2004) 1219-1228
54. Marmot M., and Kogevinas M. Elston MA. Social/economic status and disease. Annu Rev Public Health 8 (1987) 111-135
55. dog's breakfast. Anis A., Guh D., and Wang X. Prescription drug coverage varies widely across Canada. Med Care 39 (2001) 315-326
56. Bazalo G. Managed care trends in statin usage. Manag Care 10 (2001) 48-50 53-59
57. Mamdani M., and Tu J. Did the major clinical trials of statins affect prescribing behaviour?. CMAJ 164 (2001) 1695-1696
58. for the Cholesterol Treatment Trialists' (CTF) Collaborators. Baigent C., Keech A., Kearney P., et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [published correction appears in Lancet. 2005;366:1358]. Lancet 366 (2005) 1267-1278
59. Sever P., Dahlof B., Poulter N., et al. for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTLLA): A multicentre randomisedcontrolled trial. Lancet 361 (2003) 1149-1158
60. Rosuvastatin: New preparation. Opt for statins with evidence of efficacy on clinical outcome. Prescrire Int 13 (2004) 132-134
61. Lerner D. Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J 111 (1986) 383-390
62. Downs J., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with ovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
63. Shepherd J., Cobbe S., Ford I., et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N EnglJ Med 333 (1995) 1301-1307
64. Manuel D., Lim J., and Tanuseputro P. et al. Revisiting Rose: Strategies for reducing coronary heart disease. BMJ 332 (2006) 659-662
65. Manuel D., Kwong K., Tanuseputro P., et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths From coronary heart disease: Modelling study. BMJ 332 (2006) 1419